Global Lyme Disease Diagnostic Market Size study & Forecast, by Emerging Diagnostic Technology (Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nucleic acid Test), by End User (Hospitals, Public/Private

Global Lyme Disease Diagnostic Market Size study & Forecast, by Emerging Diagnostic Technology (Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nucleic acid Test), by End User (Hospitals, Public/Private Laboratories, Physicians Office) and Regional Analysis, 2022-2029

Global Lyme Disease Diagnostic Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Lyme disease is a bacterial infection caused by Borrelia burgdorferi. It is transmitted to humans through the bite of an infected black-legged tick. The symptoms of Lyme disease can be similar to other illnesses such as flu-like symptoms, fever, and fatigue, making it difficult to diagnose. In the early stages of Lyme disease, a characteristic rash called erythema migraines may develop. However, not all patients develop this rash, and in later stages, Lyme disease can affect the nervous system, heart, and joints. The key factor driving the market growth is growing prevalence of Lyme disease, favorable government initiative towards healthcare facilities, and emergence of new Lyme diagnostic tests that anticipated to create the lucrative demand for the market during forecast period.

Moreover, the rise in prevalence of Lyme disease is anticipated to create the lucrative demand for the market. For instance, according to the Centres for Disease Control and Prevention, there were 47,743 tick-borne disease cases reported in 2021, which led the development of Lyme disease diagnostic tests. For another example, the United States Fair Health Organization announced in 2022 that Lyme disease had increased significantly over the previous 15 years in the United States and had consequently become a condition of rising national concern. According to the same source, private insurance claim lines for Lyme disease diagnosis increased by 357 percent in rural areas and by 65 percent in urban areas in 2021 compared to the previous ten years. Additionally, the rising research and development in Lyme disease diagnostic is anticipated to create the lucrative opportunity for the market during forecast period. However, the lack of awareness regarding the disease stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Lyme Disease Diagnostic Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, and cohesive government initiatives for diagnosing and treatment of various diseases. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as rising Lyme disease cases and growing public and private investment in healthcare sector for better diagnostics system would create lucrative growth prospects for the Lyme Disease Diagnostic market across Asia Pacific region.

Major market player included in this report are:
Abbott Laboratories
T2 Biosystems
Canon Life Sciences
Bio Rad Laboratories
Alere Inc.
Roche Diagnostics International Ltd.
Graphene Frontiers
Covance Inc.
Immunetics Inc.
GlaxoSmithKline

Recent Developments in the Market:
In July, 2022, the United States Food and Drug Administration (USFDA) approved T2Biosystems and T2Lyme Panel. The T2Lyme Panel is intended to enable more precise early Lyme disease diagnosis, which may help to enhance care and improve patient outcomes. The T2Lyme Panel uses a patient's blood to identify bacteria that cause Lyme disease.

Global Lyme Disease Diagnostic Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Emerging Diagnostic Technology, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Emerging Diagnostic Technology:
Serological Test
Urine Antigen Tests
Lymphocytic Transformation Test
Immunofluorescent Staining
Nucleic acid Test
By End User:
Hospitals
Public/Private Laboratories
Physicians Office
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Abbott Laboratories
T2 Biosystems
Canon Life Sciences
Bio Rad Laboratories
Alere Inc.
Roche Diagnostics International Ltd.
Graphene Frontiers
Covance Inc.
Immunetics Inc.
GlaxoSmithKline

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.